• 1
    Miller RJ, Cairns JS, Bridges S, Sarver N. Human immunodeficiency virus and AIDS: insights from animal lentiviruses. J Virol 2000; 74: 71877195.
  • 2
    Spira AI, Marx PA, Patterson BK et al. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med 1996; 183: 215225.
  • 3
    Mori K, Yasutomi Y, Sawada S et al. Suppression of acute viremia by short-term postexposure prophylaxis of simian/human immunodeficiency virus SHIV-RT-infected monkeys with a novel reverse transcriptase inhibitor (GW420867) allows for development of potent antiviral immune responses resulting in efficient containment of infection. J Virol 2000; 74: 57475753.
  • 4
    Otten RA, Smith DK, Adams DR et al. Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). J Virol 2000; 74: 97719775.
  • 5
    Tsai CC, Emau P, Follis KE et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 1998; 72: 42654273.
  • 6
    Cardo DM, Culver DH, Ciesielski CA et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med 1997; 337: 14851490.
  • 7
    Frenkel LM, Cowles MK, Shapiro DE et al. Analysis of the maternal components of the AIDS clinical trial group 076 zidovudine regimen in the prevention of mother-to-infant transmission of human immunodeficiency virus type 1. J Infect Dis 1997; 175: 971974.
  • 8
    Schechter MdLR, Mendelsohn AB, Moreire RI, Moulton LH, Harrison LH. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr 2004; 35: 519525.
  • 9
    Rabaud C, Bevilacqua S, Beguinot I et al. Tolerability of postexposure prophylaxis with zidovudine, lamivudine, and nelfinavir for human immunodeficiency virus infection. Clin Infect Dis 2001; 32: 14941495.
  • 10
    Kahn JO, Martin JN, Roland ME et al. Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study. J Infect Dis 2001; 183: 707714.
  • 11
    Almeda J, Casabona J, Allepuz A et al. [Recommendations for non-occupational postexposure HIV prophylaxis. Spanish Working Group on Non-Occupational Postexposure HIV Prophylaxis of the Catalonian Center for Epidemiological Studies on AIDS and the AIDS Study Group]. Enferm Infecc Microbiol Clin 2002; 20: 391400 (in Spanish).
  • 12
    Flexner C. Post-exposure prophylaxis revisited: new CDC guidelines. Centers for Disease Control and Prevention. Hopkins HIV Rep 1998; 10: 23.
  • 13
    Puro V, Cicalini S, De Carli G et al. Post-exposure prophylaxis of HIV infection in healthcare workers: recommendations for the European setting. Eur J Epidemiol 2004; 19: 577584.
  • 14
    CDC. Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis. Morb Mortal Wkly Rep Recomm Rep 2001; 50: 152.
  • 15
    Giele CM, Maw R, Carne CA, Evans BG. Post-exposure prophylaxis for non-occupational exposure to HIV: current clinical practice and opinions in the UK. Sex Transm Infect 2002; 78: 130132.
  • 16
    CDC. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures–worldwide, 1997–2000. Morb Mortal Wkly Rep 2001; 49: 11531156.
  • 17
    Patel SM, Johnson S, Belknap SM, Chan J, Sha BE, Bennett C. Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals. J Acquir Immune Defic Syndr 2004; 35: 120125.
  • 18
    Puro V, Soldani F, De Carli G, Lazarevic Z, Mattioli F, Ippolito G. Drug-induced aminotransferase alterations during antiretroviral HIV post-exposure prophylaxis. AIDS 2003; 17: 19881990.
  • 19
    Allan DA, Behrman AJ. Lipid abnormalities in a healthcare worker receiving HIV prophylaxis. Int J STD AIDS 2001; 12: 532534.
  • 20
    Satija P, Parikh F, Aggarwal V, Sharma B, Hakim A, Pai-Dhungat JV. Indirect hyperbilirubinemia with indinavir. J Assoc Physicians India 2002; 50: 13161317.
  • 21
    Puro V, De Carli G, Orchi N et al. Short-term adverse effects from and discontinuation of antiretroviral post-exposure prophylaxis. J Biol Regul Homeost Agents 2001; 15: 238242.
  • 22
    Royce RA, Sena A, Cates W Jr, Cohen MS. Sexual transmission of HIV. N Engl J Med 1997; 336: 10721078.
  • 23
    Gray RH, Wawer MJ, Brookmeyer R et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001; 357: 11491153.
  • 24
    Vittinghoff E, Douglas J, Judson F, McKirnan D, MacQueen K, Buchbinder SP. Per-contact risk of human immunodeficiency virus transmission between male sexual partners. Am J Epidemiol 1999; 150: 306311.
  • 25
    Kaplan EH, Soskolne V, Adler B, Leventhal A, Shtarkshall RA. A model-based evaluation of a cultural mediator outreach program for HIV+Ethiopian immigrants in Israel. Eval Rev 2002; 26: 382394.
  • 26
    NCHECR. HIV/AIDS, Viral Hepatitis and Sexually Transmissible Infections in Australia. Annual Surveillance Report 2003. Sydney, Australia, National Centre in HIV Epidemiology and Clinical Research, the University of New South Wales, 2003.
  • 27
    Ammaranond P, Cunningham P, Oelrichs R et al. Rates of transmission of antiretroviral drug resistant strains of HIV-1. J Clin Virol 2003; 26: 153161.
  • 28
    Gulick RM, Ribaudo HJ, Shikuma CM et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350: 18501861.
  • 29
    Kaul BD, Gale J, McKinely G, Slater L, Huang A, Brett-Smith H. Pharmacokinetics (PK) of stavudine (d4T) extended release formulation compared with stavudine immediate release (IR) formulation as part of potent antiretroviral combination therapy. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, February, 2002, [Abstract 430].
  • 30
    Gazzard BG, Pozniak AL, Rosenbaum W et al. An open-label assessment of TMC 125–a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS 2003; 17: F49F54.